Watching Recursion Pharmaceuticals; Hearing Needham Reiterates Buy Rating, $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham has reiterated its buy rating for Recursion Pharmaceuticals, maintaining a price target of $17. The company's stock symbol is RXRX.
July 12, 2023 | 5:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham has reiterated its buy rating for Recursion Pharmaceuticals, maintaining a price target of $17.
The reiteration of a buy rating by Needham indicates a positive outlook for Recursion Pharmaceuticals. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100